CPIX · Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals reported Q1 2026 net revenue of $9.1 million, representing a 5% increase year-over-year after excluding a $3 million milestone payment from the 2025 Vibativ® China approval — indicating modest organic growth in its branded portfolio. Revenue contributions were distributed across key products: Kristalose® ($1.0M), Sancuso® ($2.9M), Vibativ® ($2.1M), Caldolor® ($1.0M), and Talicia® ($1.9M). Total operating expenses totaled $12.3 million, resulting in a GAAP net loss of $3.3 million and an adjusted loss of $1.9 million ($0.13 per share), suggesting meaningful non-cash or non-recurring expense impacts. The company simultaneously disclosed a transformative Strategic Transaction with Apotex Inc. to sell its entire U.S. commercial portfolio for $100 million in cash, pending shareholder approval and customary closing conditions. This move is explicitly intended to unlock value and refocus the company exclusively on its development-stage pipeline — particularly ifetroban, which recently earned FDA Fast Track Designation for Duchenne muscular dystrophy cardiomyopathy, following prior Orphan Drug and Rare Pediatric Disease designations. Clinical progress continues across three Phase II programs: DMD (top-line results pending FDA discussion), systemic sclerosis (enrollment complete, top-line results upcoming), and idiopathic pulmonary fibrosis (enrollment underway, interim data pending). With $11.0 million in cash and $5.2 million drawn on its credit facility, Cumberland retains financial flexibility to advance its pipeline while transitioning to a leaner, development-focused biopharmaceutical profile post-transaction.